Allostery Investments LP Buys 714,258 Shares of Zura Bio Limited $ZURA

Key Points

• Allostery Investments LP increased its stake in Zura Bio Limited by 44.2%, now holding 2,329,384 shares, which represents 4.3% of their portfolio.
• Zura Bio has a market cap of $131.34 million and currently trades at around $2.02, with a twelve month low of $0.97 and high of $5.07.
• Analysts generally rate Zura Bio with a consensus "Buy" rating and a target price of $14.00, with recent performance exceeding expectations at ($0.17) earnings per share.

Allostery Investments LP lifted its position in Zura Bio Limited (NASDAQ:ZURA - Free Report) by 44.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 2,329,384 shares of the company's stock after purchasing an additional 714,258 shares during the quarter. Zura Bio accounts for approximately 4.3% of Allostery Investments LP's holdings, making the stock its 9th biggest holding. Allostery Investments LP owned approximately 3.41% of Zura Bio worth $3,005,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Two Sigma Advisers LP bought a new stake in shares of Zura Bio in the 4th quarter worth about $32,000. ProShare Advisors LLC bought a new stake in shares of Zura Bio in the 4th quarter worth about $35,000. Wells Fargo & Company MN grew its holdings in shares of Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock worth $58,000 after purchasing an additional 9,379 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Zura Bio in the 4th quarter worth about $62,000. Finally, Nuveen LLC bought a new stake in shares of Zura Bio in the 1st quarter worth about $76,000. Institutional investors own 61.14% of the company's stock.

Wall Street Analysts Forecast Growth

ZURA has been the topic of a number of research analyst reports. Oppenheimer decreased their price objective on shares of Zura Bio from $17.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday, August 15th. HC Wainwright decreased their price objective on shares of Zura Bio from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, August 19th. Finally, Chardan Capital reissued a "buy" rating and set a $10.00 price objective on shares of Zura Bio in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Zura Bio presently has an average rating of "Buy" and a consensus target price of $14.00.

Zura Bio Trading Up 6.3%

Shares of NASDAQ:ZURA traded up $0.13 during mid-day trading on Friday, reaching $2.20. The stock had a trading volume of 368,595 shares, compared to its average volume of 341,619. The firm has a market cap of $143.04 million, a PE ratio of -3.14 and a beta of -0.02. The firm has a 50 day simple moving average of $1.61 and a two-hundred day simple moving average of $1.36. Zura Bio Limited has a twelve month low of $0.97 and a twelve month high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.